RxDoctor Payments Data

Carrie Tingley

Adult Health · Washington, NCNPI 1205201647

Payments from drug & device makers

$1,090in general payments, 2019–2025

Across 62 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$213
  • GSK$209
  • AstraZeneca$174
  • Novo Nordisk$114
  • Amgen$91
  • Abbott$84
  • plus $204 from 7 others

What the payments were for

  • Food & beverage$1,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,090 in reported general payments places this provider in the 65th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$92,232
Medicare patients
234
Services billed
2,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide113$155,746
EliquisApixaban119$121,911
OzempicSemaglutide66$91,675
Repatha SureclickEvolocumab102$89,404
JardianceEmpagliflozin60$77,360
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$69,215
JanuviaSitagliptin Phosphate35$37,492
FarxigaDapagliflozin Propanediol34$35,682
LinzessLinaclotide43$31,578
TrulicityDulaglutide21$21,978
XareltoRivaroxaban33$20,586
EntrestoSacubitril/Valsartan22$18,003
Nurtec OdtRimegepant Sulfate11$12,013
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$8,565
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$6,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$213$177,724134 claims
PfizerEliquis, Nurtec Odt$84$133,924130 claims
Novo NordiskOzempic$114$91,67566 claims
Boehringer IngelheimJardiance, Stiolto Respimat$19$85,92578 claims
GSKTrelegy Ellipta$209$69,21590 claims
AstraZenecaFarxiga$174$35,68234 claims
AbbVieLinzess$21$31,57843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 614 adult health providers in North Carolina.

Other adult health in Washington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →